Literature DB >> 20588071

Norepinephrine and serotonin transporter genes: impact on treatment response in depression.

Anna Baffa1, Christa Hohoff, Bernhard T Baune, Carsten Müller-Tidow, Nicola Tidow, Christine Freitag, Peter Zwanzger, Jürgen Deckert, Volker Arolt, Katharina Domschke.   

Abstract

BACKGROUND/AIMS: The norepinephrine transporter (NET) and serotonin transporter (5-HTT) genes constitute promising candidate genes in major depression. Seven polymorphisms in the promoter, intronic and exonic region of the NET gene, as well as serotonin-transporter-linked promoter region (5-HTTLPR) and 5-HTT rs25531 polymorphisms were analyzed with respect to antidepressant treatment response with particular attention to gender effects and subtypes of melancholic or anxious depression.
METHODS: 252 unrelated Caucasian patients (f = 142; m = 110) with major depression were genotyped for NET and 5-HTT polymorphisms. Genotype effects on Hamilton Depression Rating Scale score changes over 6 weeks of antidepressant treatment were analyzed using analysis of covariance with repeated measures.
RESULTS: There was no effect of any of the 7 investigated NET, or the two 5-HTT polymorphisms, on the overall treatment response. An additional -/CT insertion/deletion (ins/del) polymorphism (rs58532686), however, was significantly associated with melancholic depression, with a better response in 12 patients carrying the deletion. Stratification for anxious versus nonanxious depression revealed a significantly detrimental effect of the less active 5-HTTLPR S allele (p = 0.007) and 5-HTTLPR/5-HTT rs25531 haplotypes on treatment response in patients with anxious depression.
CONCLUSION: The present findings do not support a major impact of the NET and 5-HTT genes on antidepressant treatment response in major depression per se. However, there might be an impact of a -/CT ins/del polymorphism in the enhancer domain of the NET gene on treatment response in melancholic depression, which remains to be functionally investigated in future studies. The observed significant influence of the 5-HTT gene variation on antidepressant treatment in anxious depression points to anxious depression as a potential diagnostic entity of its own, requiring specific diagnostic and therapeutic attention. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20588071     DOI: 10.1159/000317285

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  19 in total

1.  Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.

Authors:  Aarthi Manoharan; Deepak Gopal Shewade; Ravi Philip Rajkumar; Surendiran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

2.  Pharmacologic treatment of dimensional anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Erica M Richards; Carlos A Zarate
Journal:  Prim Care Companion CNS Disord       Date:  2014-05-29

Review 3.  Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Bernhard T Baune
Journal:  EPMA J       Date:  2017-09-05       Impact factor: 6.543

Review 4.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 5.  Do we need pharmacogenetics to personalize antidepressant therapy?

Authors:  Cristina Lanni; Marco Racchi; Stefano Govoni
Journal:  Cell Mol Life Sci       Date:  2012-12-28       Impact factor: 9.261

Review 6.  Neurobiology of anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2013-03-11       Impact factor: 6.505

Review 7.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

8.  Influence of 5-HTT variation, childhood trauma and self-efficacy on anxiety traits: a gene-environment-coping interaction study.

Authors:  Miriam A Schiele; Christiane Ziegler; Karoline Holitschke; Christoph Schartner; Brigitte Schmidt; Heike Weber; Andreas Reif; Marcel Romanos; Paul Pauli; Peter Zwanzger; Jürgen Deckert; Katharina Domschke
Journal:  J Neural Transm (Vienna)       Date:  2016-05-04       Impact factor: 3.575

Review 9.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

10.  Affect-modulated startle: interactive influence of catechol-O-methyltransferase Val158Met genotype and childhood trauma.

Authors:  Benedikt Klauke; Bernward Winter; Agnes Gajewska; Peter Zwanzger; Andreas Reif; Martin J Herrmann; Andrea Dlugos; Bodo Warrings; Christian Jacob; Andreas Mühlberger; Volker Arolt; Paul Pauli; Jürgen Deckert; Katharina Domschke
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.